Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 21, 2014

View Archived Issues

OncoSec Medical and Plexxikon explore combination immunotherapy

AZD-1446 formulations tested for L-DOPA-induced dyskinesia

OMS-721 inhibits thrombus formation in ex vivo pathophysiologic system of aHUS

Preclinical data on effect of Nuvilex's pancreatic cancer treatment on ascites fluid formation

Canadian group discloses novel prodrugs of AR modulators

Duchenne muscular dystrophy is first target of Rosetta Genomics and Marina Biotech alliance

Cynapsus Therapeutics reports topline results from phase II trial of APL-130277

Diaxonhit initiates clinical study of Dx15 molecular test for thyroid cancer

First-in-human phase I promising results of afuresertib in recurrent ovarian cancer

ARMOR2 results: activity of galeterone in CRPC with AR-V7 variant

First demonstration of clinical activity of AG-120 a first-in-class inhibitor of mutated IDH1

New financings support Northwest Biotherapeutics' development of DCVax-L and DCVax-Direct

Veltuzumab receives FDA orphan drug status for pemphigus

AstraZeneca Canada confirms global lung cancer study of MED-14736

R-Pharm enters into an agreement with Bristol-Myers Squibb for Reyataz

BeneVir closes Series A investment

ALK seeks European approval for house dust mite sublingual allergy immunotherapy

Actelion Pharmaceuticals reports discovery of antibacterial compounds

Piramal Enterprises synthesizes novel TNF-alpha and IL-17 release inhibitors

Arena Pharmaceuticals reports development of Mas receptor modulators

Activity of novel PEGylated anti-IL-17A aptamer tested in models of rheumatoid arthritis

Gilead buys neglected disease priority review voucher from Knight Therapeutics

Evacetrapib improves cholesterol efflux in patients with dyslipidemia

Merz Pharma patents new 5-HT1A and 5-HT1B agonists

FDA approves opioid analgesic Hysingla ER

RSV F vaccine receives fast track to protect infants via maternal immunization

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...